NO964950L - Krystallinsk hydroklorid av (R)-(-)-2-{N-£4-(1,1-dioksido-3-okso-2,3-dihydro-benziso-tiazol-2-yl)-butyl|-aminometyl}-kroman - Google Patents

Krystallinsk hydroklorid av (R)-(-)-2-{N-£4-(1,1-dioksido-3-okso-2,3-dihydro-benziso-tiazol-2-yl)-butyl|-aminometyl}-kroman

Info

Publication number
NO964950L
NO964950L NO964950A NO964950A NO964950L NO 964950 L NO964950 L NO 964950L NO 964950 A NO964950 A NO 964950A NO 964950 A NO964950 A NO 964950A NO 964950 L NO964950 L NO 964950L
Authority
NO
Norway
Prior art keywords
benzisothiazol
dioxido
chroman
aminomethyl
dihydro
Prior art date
Application number
NO964950A
Other languages
English (en)
Other versions
NO307340B1 (no
NO964950D0 (no
Inventor
Alfons Grunenberg
Oliver Brehm
Michael Conrad
Dietrich Seidel
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO964950D0 publication Critical patent/NO964950D0/no
Publication of NO964950L publication Critical patent/NO964950L/no
Publication of NO307340B1 publication Critical patent/NO307340B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
NO964950A 1995-11-22 1996-11-21 Krystallinsk hydroklorid av (R)-(-)-2-{N-[4-(1,1-dioksido-3- okso-2,3-dihydro-benzisotiazol-2-yl)-butyl]-aminometyl}-kroman, legemiddel inneholdende samme, samt fremstilling og anvendelse av samme NO307340B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19543478A DE19543478A1 (de) 1995-11-22 1995-11-22 Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman

Publications (3)

Publication Number Publication Date
NO964950D0 NO964950D0 (no) 1996-11-21
NO964950L true NO964950L (no) 1997-05-23
NO307340B1 NO307340B1 (no) 2000-03-20

Family

ID=7778081

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964950A NO307340B1 (no) 1995-11-22 1996-11-21 Krystallinsk hydroklorid av (R)-(-)-2-{N-[4-(1,1-dioksido-3- okso-2,3-dihydro-benzisotiazol-2-yl)-butyl]-aminometyl}-kroman, legemiddel inneholdende samme, samt fremstilling og anvendelse av samme

Country Status (32)

Country Link
US (1) US5830908A (no)
EP (1) EP0775704B1 (no)
JP (1) JPH09143180A (no)
KR (1) KR970027079A (no)
CN (1) CN1086703C (no)
AR (1) AR004961A1 (no)
AT (1) ATE201872T1 (no)
AU (1) AU712922B2 (no)
BR (1) BR9605646A (no)
CA (1) CA2190700A1 (no)
CZ (1) CZ289730B6 (no)
DE (2) DE19543478A1 (no)
DK (1) DK0775704T3 (no)
EE (1) EE9600183A (no)
ES (1) ES2159342T3 (no)
GR (1) GR3036505T3 (no)
HU (1) HUP9603237A3 (no)
IL (1) IL119647A (no)
MX (1) MX9605741A (no)
MY (1) MY132473A (no)
NO (1) NO307340B1 (no)
NZ (1) NZ299780A (no)
PL (1) PL317090A1 (no)
PT (1) PT775704E (no)
RU (1) RU2181723C2 (no)
SG (1) SG44989A1 (no)
SI (1) SI0775704T1 (no)
SK (1) SK150096A3 (no)
TR (1) TR199600930A2 (no)
TW (1) TW449595B (no)
UA (1) UA45338C2 (no)
ZA (1) ZA969753B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CA2873524C (en) 2006-05-04 2018-02-20 Boehringer Ingelheim International Gmbh A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
ES2733348T3 (es) * 2007-08-17 2019-11-28 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con FAP
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
US20110190322A1 (en) * 2008-08-14 2011-08-04 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
CN102753161A (zh) 2009-11-27 2012-10-24 贝林格尔.英格海姆国际有限公司 基因型糖尿病患者利用dpp-iv抑制剂例如利拉利汀的治疗
WO2011138421A1 (en) 2010-05-05 2011-11-10 Boehringer Ingelheim International Gmbh Combination therapy
EP3124041A1 (en) 2010-06-24 2017-02-01 Boehringer Ingelheim International GmbH Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
ES2713566T3 (es) 2011-07-15 2019-05-22 Boehringer Ingelheim Int Derivado de quinazolina dimérico sustituido, su preparación y su uso en composiciones farmacéuticas para el tratamiento de la diabetes de tipo I y II
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5300523A (en) * 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE4138756A1 (de) * 1991-11-26 1993-05-27 Troponwerke Gmbh & Co Kg Kombination mit neuroprotektiver wirkung

Also Published As

Publication number Publication date
IL119647A0 (en) 1997-02-18
DE19543478A1 (de) 1997-05-28
PT775704E (pt) 2001-09-28
MX9605741A (es) 1997-05-31
NZ299780A (en) 1998-09-24
MY132473A (en) 2007-10-31
DE59607040D1 (de) 2001-07-12
GR3036505T3 (en) 2001-11-30
HUP9603237A3 (en) 1998-12-28
EP0775704B1 (de) 2001-06-06
ATE201872T1 (de) 2001-06-15
IL119647A (en) 1999-12-22
CZ289730B6 (cs) 2002-03-13
DK0775704T3 (da) 2001-07-23
TW449595B (en) 2001-08-11
BR9605646A (pt) 1998-08-18
CN1086703C (zh) 2002-06-26
RU2181723C2 (ru) 2002-04-27
CZ342896A3 (en) 1997-06-11
NO307340B1 (no) 2000-03-20
HUP9603237A2 (hu) 1998-01-28
ES2159342T3 (es) 2001-10-01
NO964950D0 (no) 1996-11-21
EP0775704A1 (de) 1997-05-28
SK150096A3 (en) 1997-08-06
KR970027079A (ko) 1997-06-24
PL317090A1 (en) 1997-05-26
AR004961A1 (es) 1999-04-07
JPH09143180A (ja) 1997-06-03
UA45338C2 (uk) 2002-04-15
SI0775704T1 (en) 2001-08-31
ZA969753B (en) 1997-03-25
HU9603237D0 (en) 1997-01-28
CA2190700A1 (en) 1997-05-23
SG44989A1 (en) 1997-12-19
US5830908A (en) 1998-11-03
AU7177296A (en) 1997-05-29
AU712922B2 (en) 1999-11-18
EE9600183A (et) 1997-06-16
TR199600930A2 (tr) 1997-06-21
CN1152574A (zh) 1997-06-25

Similar Documents

Publication Publication Date Title
NO964950L (no) Krystallinsk hydroklorid av (R)-(-)-2-{N-£4-(1,1-dioksido-3-okso-2,3-dihydro-benziso-tiazol-2-yl)-butyl|-aminometyl}-kroman
IT1289532B1 (it) Composti, di cloridrato di paroxetina e procedimenti per la loro preparazione
ID17275A (id) N-[4-(heteroarilmetil)fenil]-heteroarilamina
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
NO965084D0 (no) N-[3(3-cyanopyrazol[1,5-aÅpyrimidin-7-yl)fenylÅ-N-etyl-acetamid
EE9900053A (et) 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
PL334184A1 (en) Fungicidal compositions based on methyl n-(phenylacetyl)-n-(2,6-xylyl) alaninate
NO980522L (no) En-sats syntese av 2-oksazolidinonderivater
NO308537B1 (no) Antipsykotiske 4-(1H-indol-1-yl)-piperidinylderivater
NO980296D0 (no) Forbedrede terapeutiske midler
NO975220D0 (no) Ny fremgangsmåte for fremstilling av ropivacainhydrokloridmonohydrat
ID21499A (id) Proses untuk memproduksi n-(4-fluorofenil)-n-(1-metiletil)-2-[(5-(trifluorometil)-1,3,4-tiadiazol-2-il)-oksi]-asetamida
NO20006350D0 (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
MA25653A1 (fr) Derives d'amides heterocycliques.
NO974846D0 (no) Fremgangsmåte for fremstilling av Form 1 Ranitidin-Hydroklorid
NO20003145D0 (no) FremgangsmÕte for fremstilling av paroxetine-hydroklorid
NO20013715D0 (no) Karbamatderivater av diaryl 1,3,4-oksadiazolon
DE69625379D1 (de) Salze des n-[4-oxo-2-(1h-tetrazoyl-5-yl)-4h-1-benzopyran-8-yl]-4-(4-phenylbutoxy)benzamids
ITMI951587A0 (it) Epimeri del (22rs)-n-(1,1,1-trifluoro-2-fenilprop-2-il)-3-osso -4-aza-5-afa-androst-1-ene-17beta-carbossammide
AU1479800A (en) Procedure for synthesis of N-(2(((5-((dialkilamino) methyl)-2- furanyl) methyl)thyo) ethyl)-N'- alkyl-2-nitro1,1 alkenediamines and their hydrochlorides

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN MAY 2003